Educational Materials for Rheumatic Diseases

(TANGO Trial)

Recruiting at 2 trial locations

Overseen By Stephanie S Ford, Clinical Research Administration Manager, MS

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: University of Alabama at Birmingham

Disqualifiers: Lack of phone access

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

1170 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine if a new approach using videos and brochures can encourage people with rheumatic diseases to receive the updated COVID-19 vaccine. Participants will either watch a video featuring patient testimonials about vaccination and receive a brochure or learn about oral health. It is ideal for Black or Latinx adults with a rheumatic disease who have not yet received the updated COVID-19 vaccine. As an unphased trial, this study provides a unique opportunity to contribute to research that could enhance vaccine outreach and education.

Do I need to stop my current medications to join the trial?

The trial information does not specify whether you need to stop taking your current medications.

What prior data suggests that this behavioral intervention is safe?

Research has shown that storytelling and patient guidance as treatments can be well-received. One study found that storytelling improved the physical well-being of young adults with long-term rheumatologic illnesses. Participants shared their stories and found the process supportive, with no negative effects reported.

Storytelling involves sharing personal stories to teach and encourage behavioral changes, similar to learning from a friend's experience. This method has been applied in various situations without major safety issues.

Although this trial does not test a new drug, it is important to note that storytelling has been safely used for other health problems. Similar studies have found no harmful effects, suggesting it is a safe option to try in this trial. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about this trial because it explores how educational materials can improve vaccination rates among patients with autoimmune rheumatic diseases (AIRD). Unlike traditional medical treatments, this trial uses a "Storytelling" approach with videos featuring patient narratives, along with brochures and patient navigation to help patients understand COVID-19 vaccination. This method aims to enhance patient engagement and address vaccine hesitancy by making the information more relatable and accessible. By focusing on storytelling and personalized guidance, the trial could uncover new ways to support patient decision-making and improve health outcomes in this population.

What evidence suggests that this trial's treatments could be effective for improving COVID-19 vaccine uptake in patients with rheumatic diseases?

Research has shown that storytelling and patient guidance can improve health management. In this trial, participants in one arm will watch a "Storytelling" video featuring patient narratives on COVID-19 vaccination, receive a brochure on the same topic, and interact with patient navigators. One study found that storytelling videos helped young adults with long-term health issues better understand their experiences. Another study showed that patient guides, who assist people in navigating their healthcare, positively affected those with joint and muscle conditions. These methods aim to make complex information more relatable and understandable, potentially leading to better health decisions, such as getting vaccinated. Overall, these approaches might help people feel more informed and confident about health choices, including the COVID-19 vaccine. ^{4 6 7 8 9}

Who Is on the Research Team?

Maria I Danila, MD, MSc, MSPH

Principal Investigator

University of Alabama at Birmingham

Are You a Good Fit for This Trial?

This trial is for adults over 18 with autoimmune rheumatic diseases (AIRD), specifically those of Black or Latinx ethnicity who haven't had the updated COVID-19 vaccine. Participants need phone access to join.

Inclusion Criteria

Black race and/or Latinx ethnicity

I have not received the latest COVID-19 vaccine series.

Exclusion Criteria

Lack of access to phone

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Participants review storytelling video with patient narratives on COVID-19 vaccination, receive a brochure, and interact with patient navigators

3 months

Follow-up

Participants are monitored for receipt of updated COVID-19 vaccination

3 months

What Are the Treatments Tested in This Trial?

Interventions

• Testimonials and Navigation

Trial Overview

The study tests a new approach using brochures and videos about COVID-19 vaccination and oral health, plus patient narratives, to see if they encourage AIRD patients in clinics to get vaccinated.

How Is the Trial Designed?

Group I: "Storytelling" video including patient narratives, brochure and patient navigation Experimental Treatment 3 Interventions

Participants will review video with narratives on COVID-19 vaccination in patients with AIRD, receive brochure on the same topic; and interact with patient navigators.

Group II: Attention Control: "Oral Health" video and "Oral Health" brochure Active Control 2 Interventions

Participants will review video on the importance of oral health in patients with AIRD and receive brochure on the same topic.

Who Is Running the Clinical Trial?

University of Alabama at Birmingham

Lead Sponsor

Trials

1,677

Recruited

2,458,000+

National Institute on Minority Health and Health Disparities (NIMHD)

Collaborator

Trials

473

Recruited

1,374,000+

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Collaborator

Trials

508

Recruited

1,090,000+

Published Research Related to This Trial

Patient education is crucial for managing chronic rheumatic diseases, as it has been shown to improve coping strategies, reduce pain and depression, and decrease feelings of helplessness among patients.

The German Society of Rheumatology has developed a structured patient education program for rheumatoid arthritis, consisting of six group sessions led by an interdisciplinary team, which serves as a model for future programs targeting other rheumatic conditions.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Patient education--a contribution to improvement of long-term management of patients with rheumatism]. Langer, HE.[2007]

A survey of 254 rheumatic patients revealed that only 24% felt well-informed about their disease, highlighting a significant gap in patient education compared to specialized rheumatology nurses' estimates of 42%.

Patients expressed a strong interest in using digital education tools, with 89% indicating they would likely use a mobile application to learn about their condition, suggesting a promising avenue for improving disease management through technology.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Unmet Information Needs of Patients with Rheumatic Diseases: Results of a Cross-Sectional Online Survey Study in Germany. Becker, C., Diener, M., Hueber, AJ., et al.[2022]

A new website dedicated to providing information about systemic lupus erythematosus (SLE) was used by 20-30 users daily over a 24-month study period, demonstrating its popularity and accessibility for patients seeking information.

Knowledge assessments showed a significant increase in understanding of SLE among users after visiting the site, indicating that online resources can effectively enhance patient education and may be more cost-effective than traditional printed materials.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Development and assessment of a World Wide Web site for systemic lupus erythematosus patient information. Young, SP., Henderson, E., Cheseldine, DL., et al.[2017]

Patient education programs developed by the German Society of Rheumatology have effectively improved knowledge and self-efficacy in patients with various rheumatic diseases, including rheumatoid arthritis and lupus.

Randomized studies show that these programs not only enhance self-help activities but also reduce pain and disability related to arthritis, demonstrating their efficacy in managing these conditions.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Quality assurance of rheumatologic patient education]. Langer, HE., Ehlebracht-König, I., Mattussek, S.[2008]

A study involving 34 patients with rheumatic and musculoskeletal diseases identified up to 171 important items related to safety and harms that patients experience during clinical trials.

The OMERACT community largely agreed (96%) that there is sufficient qualitative data to proceed with developing a Delphi survey to better understand and measure patient-reported safety and harm in clinical trials.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Stakeholder endorsement advancing the implementation of a patient-reported domain for harms in rheumatology clinical trials: Outcome of the OMERACT Safety Working Group. Berthelsen, DB., Simon, LS., Ioannidis, JPA., et al.[2023]

AI/Learn/Rheumatology is an innovative computer-assisted interactive system designed to improve the education of health professionals about rheumatic diseases, utilizing visual and problem-solving techniques.

The system is effective for teaching various groups, including medical students and primary care physicians, making learning enjoyable and suitable for both small groups and independent study.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

AI/Learn/Rheumatology. A computer-assisted educational system for teaching about rheumatic diseases. Bridges, AJ., Dansdill, D., Anderson, J., et al.[2019]

Patient education significantly improves knowledge, self-efficacy, and health status in patients with chronic diseases, as shown in various studies, particularly in rheumatic diseases.

Incorporating physical training or rehabilitation into patient education programs leads to better outcomes, although the effect sizes for specific disease outcomes are generally low to moderate and short-lived.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Patient education in rheumatologic care--a review]. Genth, E.[2021]

A survey of 1159 health professionals across Europe and Asia showed high agreement with the EULAR recommendations for patient education in rheumatology, but lower applicability due to barriers like lack of time and training.

Identified facilitators for better implementation included tailoring education to individual needs and using group sessions, suggesting that improving training and evaluation tools could enhance the effectiveness of patient education.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Assessing acceptability and identifying barriers and facilitators to implementation of the EULAR recommendations for patient education in inflammatory arthritis: a mixed-methods study with rheumatology professionals in 23 European and Asian countries. Bennett, SE., Zangi, HA., Larsson, I., et al.[2022]

A study involving 895 patients with rheumatic diseases identified ten distinct health literacy profiles, revealing that 42% of patients had moderate to high health literacy, while 16% struggled significantly across most domains.

The identified health literacy profiles were consistent regardless of the type of rheumatic disease or the hospital, suggesting that tailored health literacy interventions can be developed for a broad range of patients in rheumatology.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Addressing Health Literacy Needs in Rheumatology: Which Patient Health Literacy Profiles Need the Attention of Health Professionals? Bakker, MM., Putrik, P., Rademakers, J., et al.[2021]

The establishment of European biologics registers for rheumatic diseases is crucial for improving drug safety assessments, and a set of seven key considerations has been identified to guide the creation of these registers.

To enhance the quality and interpretability of safety data, nine additional points for analysis and reporting have been proposed, emphasizing the importance of thoughtful design and harmonization in future studies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Dixon, WG., Carmona, L., Finckh, A., et al.[2022]

The OMERACT initiative aims to create a standardized tool for reporting adverse events in rheumatology clinical trials, which will help ensure consistent terminology and severity assessment across studies.

The proposed Rheumatology Common Toxicity Criteria Index covers multiple organ systems, but its effectiveness and practicality must be validated in clinical trials before widespread adoption.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies. Woodworth, TG., Furst, DE., Strand, V., et al.[2007]

A study analyzing 32 websites about dermatomyositis and polymyositis found that the overall quality of information was low, with a median DISCERN score of only 38 out of 80, indicating that most sources do not provide reliable guidance for patients.

The readability of the information was also poor, suggesting that patients may struggle to understand the content, which is crucial for making informed treatment decisions.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A systematic review of internet-based information on dermatomyositis and polymyositis. Haque, A., Cox, M., Sandler, RD., et al.[2021]

Observational studies and registries in rheumatology provide valuable real-world data on the safety and effectiveness of treatments, emphasizing the importance of proper study design and analysis.

The increasing interest in real-world effectiveness data is expected to lead to a rise in registries, which can offer timely insights into rheumatic treatments due to their detailed clinical information and advanced analytical tools.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Methods to analyze real-world databases and registries. Kremers, HM.[2009]

A systematic review of 93 randomized controlled trials involving 31,023 patients revealed a total of 21,498 adverse events (AEs), with 58% of these AEs being suitable for self-reporting by patients, highlighting the importance of patient perspectives in understanding treatment harms.

The study found a lack of systematic reporting on the severity of AEs, with only 9% of trials providing discernible severity grading, indicating a need for standardized frameworks to improve harm reporting in rheumatology research.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working group. Berthelsen, DB., Woodworth, TG., Goel, N., et al.[2021]

Citations

1.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC9601485/

Storytelling of Young Adults with Chronic Rheumatologic ...

Participants completed an hour-long creative writing session focused on patient experience with chronic disease. Pre- and post-questionnaires ...

2.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC10947789/

A patient-centered evaluation of a novel medical student ...

This was a cross-sectional study assessing patients' subjective experience of medical student navigators for rheumatological conditions. Current ...

3.

acrjournals.onlinelibrary.wiley.com

acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.24586

Systematic Review of Outcomes and Patient Experience With ...

Objective To conduct a systematic review on patient outcomes of virtual care compared to conventional care in rheumatoid arthritis (RA), ...

4.

researchgate.net

researchgate.net/publication/362004107_Patient_Perspectives_and_Narratives

Patient Perspectives and Narratives | Request PDF

An understanding of telerheumatology is incomplete without considering the perspective of people who are living with rheumatic conditions and their ...

5.

sciencedirect.com

sciencedirect.com/science/article/pii/S073839912300349X

The WebRA study: Opportunities and challenges in digital ...

To explore patients' perceptions of digital patient education (PE), and how this contributes to self-management of rheumatoid arthritis (RA).

6.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC10313880/

A multi-step approach to develop a “storytelling” ...

The intervention uses a video-based "storytelling" approach, with patient storytellers, a modified Delphi process, and a Health Belief Model to improve gout ...

7.

mdpi.com

mdpi.com/2227-9032/10/10/1979

Storytelling of Young Adults with Chronic Rheumatologic ...

This study used creative writing to assess storytelling in young adults with rheumatologic illnesses, showing improved physical health. It was a mixed-methods ...

8.

researchgate.net

researchgate.net/publication/364297599_Storytelling_of_Young_Adults_with_Chronic_Rheumatologic_Illnesses_A_Pilot_Study

(PDF) Storytelling of Young Adults with Chronic ...

Methods: This is a mixed-methods study of 14-21-year-olds with rheumatologic diseases followed in the Bronx, NY. Participants completed an hour- ...

9.

thepermanentejournal.org

thepermanentejournal.org/doi/10.7812/TPP/23.116

Narrative Medicine: The Power of Shared Stories to ...

Narrative medicine is a pedagogical framework that acknowledges and honors individual and collective narratives in the clinical and academic contexts.